No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand +6 more
core +7 more sources
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
Research and Practice in Thrombosis and Haemostasis, 2021 Background Coagulopathy has been reported in severely ill patients with coronavirus disease 2019 (COVID‐19). It is unclear whether outpatients with COVID‐19 who are treated with vitamin K antagonists (VKAs) have unstable anticoagulation.
Eleonora Camilleri +6 more
doaj +1 more source
The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice : systematic review and economic evaluation [PDF]
, 2015 Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
+145 more
core +1 more source
Medicina, 2021 Background and Objectives: Although the need for anticoagulation to prevent thromboembolism is increasing and non-vitamin K antagonist oral anticoagulants (NOACs) have been tried, there is still controversy about the efficacy of anticoagulation in ...
Mi-Ryung Kim +8 more
doaj +1 more source
Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]
, 2015 Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core +3 more sources
Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]
, 2016 BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core +2 more sources
Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [PDF]
, 2003 Only very limited data are available concerning patient adherence to antithrombotic medication intended to prevent a recurrent stroke. Reduced adherence and compliance could significantly influence the effects of any stroke prevention strategies.
Busse, O. +4 more
core +1 more source
Open Heart, 2023 Objective There is a substantial incidence of stroke in patients with atrial fibrillation (AF) not receiving anticoagulation. The reasons for not receiving anticoagulation are generally attributed to clinician’s choice, however, a proportion of AF ...
Ajay K Kakkar +14 more
doaj +1 more source
Micro-computed tomography for the quantification of blocked fibers in hemodialyzers [PDF]
, 2018 A novel technique based on micro-CT scanning is developed to quantify coagulation in fibers of hemodialyzers. This objectivation is needed to allow accurate assessment of thrombogenicity of dialyzers used during hemodialysis, for example when comparing ...
Boone, Matthieu +5 more
core +2 more sources
Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal [PDF]
, 2017 Current guidelines support the well-established clinical practice that patients who present with atrial fibrillation (AF) of less than 48 hours duration should be considered for cardioversion, even in the absence of pre-existing anticoagulation. However,
Rankin, Alastair J., Rankin, Stephen H.
core +1 more source